Anaptysbio (ANAB) Return on Capital Employed (2017 - 2026)
Anaptysbio (ANAB) posted Return on Capital Employed of 13.36% for Q1 2026, down 10.7% on a QoQ basis from 14.96% in Q4 2025, and up 3789.0% year-over-year from 0.34% in Q1 2025.
Anaptysbio (ANAB) Return on Capital Employed (2017 - 2026) Analysis & Trends
Anaptysbio's Return on Capital Employed history runs 10 years deep, the most recent figure standing at 13.36% for Q1 2026.
- Quarterly Return on Capital Employed rose 3789.0% year-over-year to 13.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.36% (up 3789.0% YoY) and the FY2025 annual result came in at 12.42%, up 3962.0% from the prior year.
- Return on Capital Employed was 13.36% for Q1 2026 at Anaptysbio, down from 14.96% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 14.96% in Q4 2025 and bottomed at 43.17% in Q2 2024.
- A 5-year average of 21.51% and a median of 24.53% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 2229 bps — and 2025, when it soared 4090 bps.
- Anaptysbio's Return on Capital Employed stood at 19.57% in 2022, then slumped by 94 bps to 38.02% in 2023, then surged by 32 bps to 25.94% in 2024, then soared by 158 bps to 14.96% in 2025, then retreated by 11 bps to 13.36% in 2026.
- Business Quant data shows ANAB's Return on Capital Employed at 13.36% in Q1 2026, 14.96% in Q4 2025, and 9.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Anaptysbio | 1.58 Bn | 1.29 Bn | - | 13.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.36% |
| Dec 31, 2025 | 14.96% |
| Sep 30, 2025 | -9.37% |
| Jun 30, 2025 | -25.10% |
| Mar 31, 2025 | -24.53% |
| Dec 31, 2024 | -25.94% |
| Sep 30, 2024 | -35.39% |
| Jun 30, 2024 | -43.17% |
| Mar 31, 2024 | -40.88% |
| Dec 31, 2023 | -38.02% |
| Sep 30, 2023 | -32.02% |
| Jun 30, 2023 | -28.44% |
| Mar 31, 2023 | -23.44% |
| Dec 31, 2022 | -19.57% |
| Sep 30, 2022 | -20.39% |
| Jun 30, 2022 | -16.39% |
| Mar 31, 2022 | -11.43% |
| Dec 31, 2021 | -10.98% |
| Sep 30, 2021 | 1.90% |
| Jun 30, 2021 | -2.53% |